HDAC9 and diffuse large B-cell lymphoma: Clinical translational research shows that in a Phase II clinical trial of newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL) (n=100), oral HDAC inhibitor Tucidinostat (20 mg per dose) in combination with the R-CHOP regimen achieved an 86% complete response rate (91).